Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortOral JAK inhibitor for rheumatoid arthritis, eczema and alopecia areata.Tablet that blocks inflammation signals for arthritis and colitis.
Body systemJoints & ImmunityJoints & Immunity
Drug classJAK inhibitorsJAK inhibitors
SupplyPrescription onlyPrescription only
Main usesRheumatoid arthritis, Atopic dermatitis (eczema), Alopecia areata, Hospitalised COVID-19Rheumatoid arthritis, Psoriatic arthritis, Ulcerative colitis, Ankylosing spondylitis
How it worksCalms immune signalling inside cells.Blocks the relay inside immune cells that passes on inflammation signals.
Starts workingWeeks—
Half-lifeAbout 12 hoursAbout 3 hours
Typical adult dose4 mg once a day (2 mg if risk factors or after response).5 mg twice a day (10 mg twice a day for induction in ulcerative colitis).
FormsTabletTablet, Modified-release tablet, Oral solution
Common side effectsUpper respiratory infections, Raised cholesterol, Nausea, Cold soresCold-like infections, Headache, Diarrhoea, Raised cholesterol
Serious side effectsSerious infections, Blood clots, Heart attack and stroke, CancersShingles, Blood clots, Heart attacks and cancer in at-risk groups, Serious infections
Don't take ifActive serious infection; Active TB; Pregnancy; Severe liver impairment—
AlcoholBest to limit. Alcohol may add to liver strain.—
PregnancyUsually avoidedAvoid in pregnancy.Usually avoidedNot recommended.
BreastfeedingUsually avoidedAvoid.—
In use since—2012
Brand namesUnited States: OlumiantUnited Kingdom: OlumiantIndia: Olumiant, Bariciti, Baricitinib (generic)United States: XeljanzUnited Kingdom: XeljanzIndia: Tofacinix, Xeljanz
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H—
ATC codeL04AA37—

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker